Free Trial
→ Tomorrow's Stock of the Day (From The Early Bird) (Ad)tc pixel Free TRVN Stock Alerts

Trevena (TRVN) Competitors

Trevena logo
$0.01 0.00 (0.00%)
As of 05/13/2026
Compare

TRVN vs. SCPS, CARM, VAXX, SYRS, and NAVB

Should you buy Trevena stock or one of its competitors? MarketBeat compares Trevena with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trevena include Scopus BioPharma (SCPS), Carisma Therapeutics (CARM), Vaxxinity (VAXX), Syros Pharmaceuticals (SYRS), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry.

How does Trevena compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

13.6% of Trevena shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Trevena N/A N/A -119.55%

Scopus BioPharma has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market. Comparatively, Trevena has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Scopus BioPharma has higher earnings, but lower revenue than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Trevena$443K0.02-$40.29M-$47.04N/A

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Trevena Neutral

Summary

Scopus BioPharma and Trevena tied by winning 3 of the 6 factors compared between the two stocks.

How does Trevena compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Trevena has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company Net Margins Return on Equity Return on Assets
Carisma Therapeutics-254.28% N/A -192.17%
Trevena N/A N/A -119.55%

Trevena has lower revenue, but higher earnings than Carisma Therapeutics. Trevena is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00
Trevena$443K0.02-$40.29M-$47.04N/A

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Carisma Therapeutics Neutral
Trevena Neutral

44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Carisma Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Trevena has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Carisma Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Carisma Therapeutics is more favorable than Trevena.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67
Trevena
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Carisma Therapeutics beats Trevena on 10 of the 14 factors compared between the two stocks.

How does Trevena compare to Vaxxinity?

Trevena (NASDAQ:TRVN) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Vaxxinity N/A N/A N/A

Trevena has higher revenue and earnings than Vaxxinity. Trevena is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
VaxxinityN/AN/A-$56.93M-$0.45N/A

In the previous week, Trevena's average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company Overall Sentiment
Trevena Neutral
Vaxxinity Neutral

13.6% of Trevena shares are owned by institutional investors. Comparatively, 82.9% of Vaxxinity shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 64.1% of Vaxxinity shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Trevena has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Vaxxinity has a beta of -74.37, indicating that its stock price is 7,537% less volatile than the broader market.

Summary

Vaxxinity beats Trevena on 5 of the 8 factors compared between the two stocks.

How does Trevena compare to Syros Pharmaceuticals?

Trevena (NASDAQ:TRVN) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

13.6% of Trevena shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Trevena's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Syros Pharmaceuticals N/A -3,369.56%-97.04%

Trevena has higher revenue and earnings than Syros Pharmaceuticals. Trevena is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A

Trevena has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

In the previous week, Trevena's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Trevena Neutral
Syros Pharmaceuticals Neutral

Summary

Syros Pharmaceuticals beats Trevena on 6 of the 10 factors compared between the two stocks.

How does Trevena compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Trevena N/A N/A -119.55%

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Trevena. Trevena is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Trevena$443K0.02-$40.29M-$47.04N/A

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Trevena has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Trevena Neutral

Summary

Navidea Biopharmaceuticals beats Trevena on 5 of the 8 factors compared between the two stocks.

Get Trevena News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRVN vs. The Competition

Export
MetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$11K$935.60M$6.34B$12.37B
Dividend YieldN/A4.84%2.80%5.35%
P/E Ratio0.001.4820.6625.63
Price / Sales0.02115.81542.6376.59
Price / CashN/A20.0743.2656.33
Price / Book0.008.119.936.97
Net Income-$40.29M-$3.91M$3.55B$333.62M
7 Day PerformanceN/A9.43%1.70%1.09%
1 Month PerformanceN/A76.62%0.49%3.08%
1 Year PerformanceN/A140.55%39.41%35.68%

Trevena Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRVN
Trevena
N/A$0.01
flat		N/A-99.1%$11K$443KN/A40
SCPS
Scopus BioPharma
N/A$0.00
+50.0%		N/AN/A$25KN/AN/A9
CARM
Carisma Therapeutics
2.4008 of 5 stars		$0.00
-20.0%		$1.00
+249,900.0%		-99.9%$17K$10.77M0.0020
VAXX
Vaxxinity
N/A$0.00
flat		N/A-99.0%$13KN/AN/A90
SYRS
Syros Pharmaceuticals
N/A$0.00
+100.0%		N/A-99.4%$11K$386KN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TRVN) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel